Leerink Partners on Ultragenyx Pharma (RARE): FDA BLA acceptance positions co for two approvals, $150M oppty
Leerink Partners analyst Joseph Schwartz reiterated an Outperform rating and $60.00 price target on Ultragenyx Pharma (NASDAQ: RARE)The analyst commented ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)